Extended half-life factor VIII for immune tolerance induction in haemophilia

Haemophilia

Volumn 22, Issue 6, 2016, Pages e552-e554

  Malec, L M ^a,b   Journeycake, J ^c,d   Ragni, M V ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b Hemophilia Center of Western Pennsylvania   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Program Pauline Allen Gill Center for Cancer and Blood Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8;

CHILD; FEMALE; HALF LIFE TIME; HEMOPHILIA A; HUMAN; IMMUNOLOGY; INFANT; MALE; METABOLISM;

CHILD; FACTOR VIII; FEMALE; HALF-LIFE; HEMOPHILIA A; HUMANS; INFANT; MALE;

EID: 84995962587     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.13064     Document Type: Letter

References (10)

1. Manco-Johnson MJ, Abshire TC, Shapiro AD et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535–44.
2. World Federation of Hemophilia. Guidelines for the management of hemophilia (2nd Edition). Haemophilia 2013; 19: e1–47.
3. Powell JS, Josephson NC, Quon D et al. Safety and prolonged activity of recombinant factor FVIII Fc fusion protein in hemophilia A patients. Blood 2012; 119: 3031–7.
4. Mahlangu J, Powell JS, Ragni MV et al. Phase 3 study of recombinant factor VIIIFc fusion protein in severe hemophilia A. Blood 2014; 123: 317–25.
5. Collins PW, Blanchette VW, Fischer K et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. JTH 2009; 7: 413–20.
6. Liu T, Hoehn T, Hoehn S, Patarroyo-White S, Pierce G, Jiang H. Evaluation of antibody responses to rFVIIIFc compared to Xyntha and Advate in hemophilia A mice. Haemophilia 2012; 18(Suppl S3): 41.
7. Ragni MV, Alabek M, Malec LM. Inhibitor development in two cousins receiving full-length factor VIII and factor VIII-Fc fusion protein. Haemophilia 2016. doi: 10.1111/hae.13032.
8. De Groot A, Moise L, McMurry JA et al. Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”. Blood 2008; 112: 3303–11.
9. Hay CR, DiMichele DM; for the International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335–44.
10. Miller CH, Platt SJ, Rice AS, Kelly F, Soucie JM; Hemophilia Inhibitor Research Study Investigators. Validation of Nijmegen-Bethesda assay modifications to allow inhibitor measurement during replacement therapy and facilitate inhibitor surveillance. JTH 2012; 10:1055–61.